MAPT and Alzheimer disease: In contrast, very recently, the first HDAC positron emission tomography (PET) data from AD patients using [11C] martinostat, a PET tracer that recognizes class I HDACs in the brain, revealed global reduced HDAC I levels in AD-affected brain regions where amyloid and tau are high [175].